Updated:
Zhongke Zhanwang Venture Investment
Zhongke Zhanwang Venture Investment operates as a Beijing-based asset manager focused on early-stage venture and seed investing.
Zhongke Zhanwang Venture Investment
Zhongke Zhanwang Venture Investment operates as a Beijing-based asset manager focused on early-stage venture and seed investing. The firm's name, which translates roughly to 'China Science Prospect,' signals an affiliation with the Chinese Academy of Sciences (CAS) ecosystem, a network that has produced numerous spinout technology companies. This structural tie to state research institutions shapes its deal flow and differentiates it from purely financial venture firms. The firm targets seed and early venture rounds, concentrating on technology commercialization from academic and national laboratories. Sectors of focus appear tightly coupled with CAS priorities — advanced materials, life sciences, semiconductor tooling, and precision instrumentation. Rather than broad consumer tech, Zhongke Zhanwang's capital flows into hard-science startups where technical risk is high but competitive moats are, in theory, wider. Its investment structure likely emphasizes direct equity in portfolio companies, with board observation or seats linked to the technical advisory capabilities of its parent institutions. Team size and total deployment figures remain undisclosed, consistent with many Chinese early-stage venture firms that operate without public-facing limited partner reporting. The firm's positioning inside the Beijing technology corridor places it within walking distance of key research universities and national laboratories. No publicly known parallel philanthropic structures, co-investment clubs, or international offices have been identified, which suggests a concentrated, locally-focused mandate. Zhongke Zhanwang's structural differentiator is its connection to China's state research apparatus. Unlike a generic venture firm, its pipeline is not purely market-sourced; it relies on the intellectual property and talent graduating from CAS institutes. This creates a sourcing model with asymmetrical access to cutting-edge research, though it also binds the firm's investment thesis to the strategic priorities of state-sponsored science, a governance feature that distinguishes it from independent, return-maximizing venture capital managers.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Beijing
Corporate office
Beijing, China
Frequently asked questions
What is Zhongke Zhanwang's connection to the Chinese Academy of Sciences?
The firm's name translates to 'China Science Prospect,' and it operates within the orbit of the Chinese Academy of Sciences (CAS) ecosystem. Its deal flow leans heavily on technology commercialization from CAS-affiliated research institutes, giving it preferential access to spinout companies in advanced materials and life sciences. This relationship is not merely branding; it defines the firm's sourcing pipeline and technical evaluation capabilities.
What investment stages does Zhongke Zhanwang typically target?
The firm targets seed and early-stage venture rounds, often as the first institutional capital into a company. It focuses on technology startups emerging from China's national research infrastructure, where technical validation is more critical than commercial traction. The mandate is overwhelmingly early-stage, with no public record of growth-equity or buyout activity.
How does Zhongke Zhanwang source its deal flow?
Deal flow originates primarily from the Chinese Academy of Sciences network — research institutes, university laboratories, and affiliated technology transfer offices. This differs from market-sourced venture firms that rely on founder outreach or accelerator programs. The structural tie to CAS provides access to highly technical, pre-commercial companies that external VCs rarely see.
Does Zhongke Zhanwang operate independently or is it a direct arm of the state?
Zhongke Zhanwang is structured as an asset manager, not a direct government agency. However, its investment priorities align closely with state scientific objectives, and its limited partners or sponsors likely include state-affiliated capital. Its independence is functional for deal execution, but its strategic direction reflects the priorities of China's national research agenda.
How large is Zhongke Zhanwang's investment team?
The firm has not publicly disclosed its team size or total assets. Given its specialized, deep-tech focus and reliance on technical due diligence from CAS scientists, the investment team is likely small and comprised of professionals with advanced scientific degrees rather than traditional finance backgrounds.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: